OGN / Healthy Dividends: Organon's Dividend Bolsters The Long-Term Investment In A Fresh Ticker

Organon & Co (NYSE:OGN ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO M more_horizontal

The stock of junk-rated Organon & Co. has lost more than 40% since my first article, largely due to interest rates continuing to rise. I take a close more_horizontal

Organon & Co. stock is down 30% year-to-date and 40% below its 52-week highs. OGN offers a dividend yield of 5.8%, making it an attractive option for more_horizontal

Organon & Co (NYSE:OGN ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Mat more_horizontal

Organon & Co reported better-than-expected second-quarter results on Tuesday, helped by strong demand for its women's heath products and biosimilar dr more_horizontal

The "Halftime Report" traders give their top picks to watch for the second half. more_horizontal

Organon & Co. OGN, -1.15% and partner Samsung Bioepis Co. Ltd. said Wednesday they have launched their Humira biosimilar Hadlima in the U.S. The move more_horizontal

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis more_horizontal